Q-omics provides the consensus-scored LINC00412 profile across patient tissues and cancer cell-line models. LINC00412 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC00412 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LINC00412 RNA expression shows 13,923 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, COAD, and UVM as cancer lineages where LINC00412 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00412 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00412 survival associations across molecular data types. LINC00412 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00412 RNA expression–survival associations across cancer types. High LINC00412 expression shows unfavorable associations in KIRC and LIHC, but favorable associations in STAD, SKCM, BRCA and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for LINC00412 RNA expression.
This table summarizes LINC00412 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00412. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00412 shows lower tumor expression in KICH, UCEC and KIRC and higher tumor expression in COAD, LIHC and READ. The COAD box plot shows higher LINC00412 RNA expression in tumor versus normal tissue (log2 FC = +0.341, t-test p < 0.001).
This table shows molecular features associated with LINC00412 in patient tissues and cancer cell lines. In patient samples, LINC00412 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
